Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06513091 · ClinicalTrials.gov registry record
US National TOP Registry
A clinical trial of Lung Transplant, sponsored by TransMedics.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 7
- Study locations
NCT06513091: Recruiting study of Lung Transplant, sponsored by TransMedics.
NCT06513091 is a study of Lung Transplant that is actively recruiting participants, run by TransMedics. The registered enrollment target is 10,000 participants, above the 609-participant average among 15 other Lung Transplant trials with a reported enrollment target (1542% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06513091, a study of Lung Transplant, is actively recruiting participants, sponsored by TransMedics.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
The objective of this Registry is to collect short and long-term post-transplant clinical outcome data of all donor lungs preserved and assessed on the OCS Lung System and to document the performance of the OCS device in the real-world setting after FDA approval in the US.
Primary Outcome
Recipients' one-year patient and graft survival rates
Conditions Studied
Interventions
- DEVICE OCS Lung
Study Locations (7)
Texas
- Baylor Scott & White Research Institute - Dallas
- Baylor College of Medicine - Houston
Arizona
- St. Joseph's Hospital & Medical Center - Phoenix
California
- Stanford University School of Medicine - Stanford
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Duke University - Durham
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2039-11 |
What NCT06513091 shows while recruiting
NCT06513091 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 609-participant average among 15 other Lung Transplant trials with a reported enrollment target (1542% higher).
The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Lung is the first listed.
NCT06513091 lists 7 locations in 6 states (Texas, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06513091 about?
NCT06513091 is a clinical study titled "US National TOP Registry". The objective of this Registry is to collect short and long-term post-transplant clinical outcome data of all donor lungs preserved and assessed on the OCS Lung System and to document the performance of the OCS device in the real-world setting after FDA approval in the US.
What is the current status of trial NCT06513091?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2025-01-23. Estimated completion is 2039-11.
What conditions does trial NCT06513091 study?
This clinical trial studies the following conditions: Lung Transplant.
What interventions are being tested in trial NCT06513091?
The interventions under investigation include: OCS Lung (DEVICE).
Who is sponsoring clinical trial NCT06513091?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06513091 being conducted?
This trial has 7 study locations across Arizona, California, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06513091's enrollment target sits among peer trials
10,000 1st of 15 higher than 15 of 15 other Lung Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
RECRUITING
-
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
RECRUITING · NA
-
Planned Semi-Elective Lung Tx Study
RECRUITING · NA
-
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
RECRUITING · Phase 2
-
Tocilizumab in Lung Transplantation
RECRUITING · Phase 2
-
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI